Another important result of our study is substantiation of the pioneer perspective of personalized approaches to the treatment of patients with neurodegenerative (multiple sclerosis, parkinsonism, Alzheimer’s disease) and neurodevelopmental (autism/ASD) diseases, when the pathogenetically essential fact is insufficiency of antioxidation mechanisms, which could be compensated (at least, in a fraction of patients) by drug inducers of NRF2. This evidence concerns the gene NFE2L2 and Parkinsonism.